The setup: Cempra, Inc. (CEMP) is a clinical-stage pharmaceutical company that develops differentiated anti-infective drugs. It has two lead products in advanced clinical trials, solithromycin — which met objectives against community-acquired bacterial pneumonia in two Phase 3 trials — and Taksta (fusidic acid), which will present Phase 2-3 trial results in December. This antibiotic has been used in Europe for years, so I like the catalyst.
The back story: Cempra announced plans to merge with another anti-infective drug developer, Melinta Therapeutics, giving them a much wider portfolio of products. It looks like a great move for both companies. Melinta got FDA approval in June for Baxdela, a novel antibiotic, in treatment of acute bacterial skin and skin-structure infections, including MRSA. Baxdela is in Phase 3 trials for bacterial pneumonia; a trial against urinary tract infections is planned.
How I’m playing it: I went long on CEMP on Oct. 2, buying 1,000 shares at $3.25. It’s undervalued and I’m looking to build a bigger position, but I want to see how the market reacts to the merger and see if it perceives the deal as a dilution.
Personally, I anticipate staying bullish on this name after the merger closes, which is expected this month, but I will watch the action before deciding if I can build a full position in the stock.
Kyle Dennis runs Kyle Dennis’ Biotech Breakouts (biotechbreakouts.com). He is an event-based trader, who prefers low-priced and small-cap biotech stocks. He bought 1,000 shares of CEMP at $3.25 on Oct. 2. He sold his 1,000-share position in MNOV Oct. 2 for a 25 percent gain, as described above.
You may also like
Exclusive System Tracks Wall St. Insiders
“Dollar Ace Simply Exposes Information That Wall Street Wants To Keep Quiet” Said Kyle Dennis
“One member, Wesley M., has already reported 360%+ gains in just a few short days. Don’t miss this!”
(Reserve Access Now)
“What Recession?!” Jason Bond nets $55,060 in realized profit in One Day
After going 6 for 6 on profitable trades recently, we caught up with Jason to ask how he did it.
Check out Jason’s exclusive interview revealing this tightly guarded strategy. (Watch Now)
RagingBull.com Co-Founder, Jeff Bishop, Launches High Conviction Trade Service
“We listen to our clients and we give them EXACTLY what they want, so we designed a service to deliver 1 trade, 1 time a week, with a 100%+ PROFIT TARGET, directly to your inbox every Monday before the market opens. (Read More)